Very low lipoprotein(a) and increased mortality risk after myocardial infarction

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F21%3A00081536" target="_blank" >RIV/00023001:_____/21:00081536 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064190:_____/21:N0000038 RIV/00216208:11120/21:43922056 RIV/00216208:11110/21:10431419

Výsledek na webu

<a href="https://www.ejinme.com/article/S0953-6205(21)00135-7/pdf" target="_blank" >https://www.ejinme.com/article/S0953-6205(21)00135-7/pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ejim.2021.04.012" target="_blank" >10.1016/j.ejim.2021.04.012</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Very low lipoprotein(a) and increased mortality risk after myocardial infarction

Popis výsledku v původním jazyce

Background: Inconclusive data exist on risk associated with Lp(a) in patients after myocardial infarction (MI). Aims of the present study were to evaluate the association of Lp(a) level with total mortality and recurrent cardiovascular events. Design and methods: Single center prospective registry of consecutive patients hospitalized for acute myocardial infarction between June 2017 and June 2020 at a large tertiary cardiac center with available blood samples drawn &lt;24h of admission. Results: Data from 851 consecutive patients hospitalized for MI were evaluated. During the median follow-up of 19 months (interquartile range 10-27), 58 (6.8%) patients died. Nonlinear modelling revealed a U-shaped as-sociation between Lp(a) and total mortality risk. Compared to patients with Lp(a) ranging between 10-30 nmol/L and after multivariate adjustment, total mortality risk was increased both in patients with Lp(a) 7 nmol/L (hazard ratio (HR) 4.08, 95% confidence interval (CI) 1.72-9.68) and Lp(a) 125 nmol/L (HR 2.92, 95% CI 1.16-7.37), respectively. Similarly, the risk of combined endpoint of acute coronary syndrome recurrence or cardiovascular mortality was increased both in patients with low (sub-HR 2.60, 95% CI 1.33-5.08) and high (sub-HR 2.10, 95% CI 1.00-4.39) Lp(a). Adjustment for heart failure signs at the time of hospitalization weakened the association with total mortality and recurrent cardiovascular events. Conclusions: In the present analysis, both high and low concentrations of Lp(a) were associated with an increased risk of total mortality and recurrent cardiovascular events after MI. The excess of mortality associated with Lp(a) was partially attributable to more prevalent heart failure.

Název v anglickém jazyce

Very low lipoprotein(a) and increased mortality risk after myocardial infarction

Popis výsledku anglicky

Background: Inconclusive data exist on risk associated with Lp(a) in patients after myocardial infarction (MI). Aims of the present study were to evaluate the association of Lp(a) level with total mortality and recurrent cardiovascular events. Design and methods: Single center prospective registry of consecutive patients hospitalized for acute myocardial infarction between June 2017 and June 2020 at a large tertiary cardiac center with available blood samples drawn &lt;24h of admission. Results: Data from 851 consecutive patients hospitalized for MI were evaluated. During the median follow-up of 19 months (interquartile range 10-27), 58 (6.8%) patients died. Nonlinear modelling revealed a U-shaped as-sociation between Lp(a) and total mortality risk. Compared to patients with Lp(a) ranging between 10-30 nmol/L and after multivariate adjustment, total mortality risk was increased both in patients with Lp(a) 7 nmol/L (hazard ratio (HR) 4.08, 95% confidence interval (CI) 1.72-9.68) and Lp(a) 125 nmol/L (HR 2.92, 95% CI 1.16-7.37), respectively. Similarly, the risk of combined endpoint of acute coronary syndrome recurrence or cardiovascular mortality was increased both in patients with low (sub-HR 2.60, 95% CI 1.33-5.08) and high (sub-HR 2.10, 95% CI 1.00-4.39) Lp(a). Adjustment for heart failure signs at the time of hospitalization weakened the association with total mortality and recurrent cardiovascular events. Conclusions: In the present analysis, both high and low concentrations of Lp(a) were associated with an increased risk of total mortality and recurrent cardiovascular events after MI. The excess of mortality associated with Lp(a) was partially attributable to more prevalent heart failure.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

<a href="/cs/project/NV19-09-00125" target="_blank" >NV19-09-00125: Nové nástroje ke zlepšení kardiovaskulární prevence po infarktu myokardu</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European journal of internal medicine

ISSN

0953-6205

e-ISSN

—

Svazek periodika

91

Číslo periodika v rámci svazku

September 2021

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

7

Strana od-do

33-39

Kód UT WoS článku

000690383400007

EID výsledku v databázi Scopus

2-s2.0-85105484387